Cortney Smith
Psychiatric/Mental Health · Washington, PANPI 1861935058
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,974 of the $227,099 with a category attached, or 75.3%. 31 manufacturers reported payments, led by AbbVie at 53.9% of the total. 2025 is the largest year on record at $114,510, more than ten times the $4,321 reported in 2021. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,922 payments — averaging $118.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$122K
- Neurocrine Biosciences, Inc.$80K
- Otsuka America Pharmaceutical, Inc.$5K
- Teva Pharmaceuticals USA, Inc.$3K
- Alkermes, Inc.$3K
- Lundbeck LLC$2K
- plus $13K from 25 others
What the payments were for
- Consulting fees$12,1885%
- Speaking & faculty fees$170,97475%
- Travel & lodging$9,5484%
- Food & beverage$34,04315%
- Education$3460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 385 | $122,409 |
| Neurocrine Biosciences, Inc. | 266 | $79,638 |
| Otsuka America Pharmaceutical, Inc. | 250 | $4,655 |
| Teva Pharmaceuticals USA, Inc. | 128 | $2,733 |
| Alkermes, Inc. | 96 | $2,597 |
| Lundbeck LLC | 139 | $1,950 |
| Supernus Pharmaceuticals, Inc. | 136 | $1,786 |
| Axsome Therapeutics, Inc. | 74 | $1,689 |
| Almatica Pharma LLC | 24 | $1,590 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,229 |
| Johnson & Johnson | 71 | $1,204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,125 |
| Corium, LLC | 69 | $1,011 |
| E.r. Squibb & Sons, L.L.C. | 28 | $799 |
| Vanda Pharmaceuticals Inc. | 23 | $786 |
| Idorsia Pharmaceuticals US Inc | 23 | $522 |
| Sunovion Pharmaceuticals Inc. | 30 | $346 |
| Astellas Pharma US Inc | 4 | $173 |
| Eisai Inc. | 10 | $167 |
| Jazz Pharmaceuticals Inc. | 4 | $152 |
| Indivior Inc. | 6 | $101 |
| Ironshore Pharmaceuticals Inc. | 4 | $90 |
| Sage Therapeutics, LLC | 4 | $73 |
| Neos Therapeutics, LP | 4 | $69 |
| Novo Nordisk | 2 | $51 |
| Collegium Pharmaceutical, Inc. | 2 | $46 |
| GSK | 2 | $31 |
| Medline Industries LP | 1 | $29 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$112,642
- INGREZZA$74,193
- ARISTADA$1,461
- LOREEV XR$1,196
- LYBALVI$969
- Auvelity$590
- UZEDY$497
- REXULTI$494
- Fanapt$486
- QELBREE$383
- ABILIFY MAINTENA$372
- ARISTADA INITIO$365
- COBENFY$360
- ABILIFY ASIMTUFII$249
- Austedo XR$125
- Veozah$125
- AUSTEDO$124
- CAPLYTA$118
- INVEGA SUSTENNA$113
How this compares
$227,099 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 67 | $555,856 |
| VraylarCariprazine Hcl | 148 | $204,989 |
| Invega SustennaPaliperidone Palmitate | 45 | $139,170 |
| RexultiBrexpiprazole | 97 | $138,906 |
| Abilify MaintenaAripiprazole | 43 | $113,897 |
| TrintellixVortioxetine Hydrobromide | 79 | $40,660 |
| CaplytaLumateperone Tosylate | 23 | $38,482 |
| QuviviqDaridorexant Hcl | 30 | $13,940 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,289 |
| Lurasidone Hcl | 35 | $8,104 |
| Trazodone Hcl | 351 | $4,834 |
| Gabapentin | 156 | $3,622 |
| Lisdexamfetamine Dimesylate | 11 | $3,413 |
| Bupropion XlBupropion Hcl | 171 | $3,184 |
| Aripiprazole | 91 | $2,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $79,638 | $555,85667 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $4,655 | $252,803140 claims |
| AbbVieVraylar | $122,409 | $204,989148 claims |
| Johnson & JohnsonInvega Sustenna | $1,204 | $139,17045 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,125 | $40,66079 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,229 | $38,48223 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $522 | $13,94030 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,689 | $12,28911 claims |
| Almatica Pharma LLCSertraline Hcl | $1,590 | $1,359151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Washington
- Michelle CohenWashington$62K
- Kimberly GarciaAllentown$573K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
- Dylan KilmerGreenfield Township$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.